HUP0104255A2 - Inhalációra alkalmas gyógyászati készítmény - Google Patents
Inhalációra alkalmas gyógyászati készítményInfo
- Publication number
- HUP0104255A2 HUP0104255A2 HU0104255A HUP0104255A HUP0104255A2 HU P0104255 A2 HUP0104255 A2 HU P0104255A2 HU 0104255 A HU0104255 A HU 0104255A HU P0104255 A HUP0104255 A HU P0104255A HU P0104255 A2 HUP0104255 A2 HU P0104255A2
- Authority
- HU
- Hungary
- Prior art keywords
- lipid
- mixture
- phosphatidylcholine
- molar ratio
- inhalation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 12
- 239000000203 mixture Substances 0.000 abstract 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 6
- 102000009027 Albumins Human genes 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 2
- 229930182558 Sterol Natural products 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 2
- 150000003432 sterols Chemical class 0.000 abstract 2
- 235000003702 sterols Nutrition 0.000 abstract 2
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
Abstract
A találmány bioaktív vegyület inhalálás útján történő beadásáraalkalmas rendszerre vonatkozik, mely: (a) a biológiailag aktívvegyületből és egy lipidkeverékből; és (b) egy inhalációsbejuttatóeszközből áll, ahol a lipidkeverék (1) egy foszfatidil-kolinból, negatívan töltött lipidből és szterinből álló 1-20:1-10:0,5-5 mólarányú első keveréket; (2) egy foszfatidil-kolinból, negatívantöltött lipidből és albuminból álló 1-10:1-10:0,0-1 mólarányú másodikkeveréket; (3) egy foszfatidil-kolinból, pozitívan töltött lipidből ésfoszfatidil-etanol-aminból álló 1-20 : 0,5-20 : 1-10 mólarányúharmadik keveréket; (4) egy foszfatidil-kolinból, negatívan töltöttlipidből és foszfatidil-etanol-aminból álló 1-20 : 1-10 : 1-10mólarányú negyedik lipidkeveréket; (5) egy foszfatidil-kolinból,pozitívan töltött lipidből és albuminszármazékból álló 1-20 : 0,5-20 :0,1-10 mólarányú ötödik lipidkeveréket; vagy (6) egy foszfatidil-kolinból, pozitívan töltött lipidből és szterinszármazékból álló 1-20: 0,5-20 : 0,5-5 mólarányú hatodik lipidkeveréket tartalmaz, ahol abioaktív anyag és a lipidkeverék tömegaránya 10 : 1-1 : 5 00. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10806798P | 1998-11-12 | 1998-11-12 | |
US10812698P | 1998-11-12 | 1998-11-12 | |
PCT/US1999/026858 WO2000027359A1 (en) | 1998-11-12 | 1999-11-12 | An inhalation system |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104255A2 true HUP0104255A2 (hu) | 2002-03-28 |
HUP0104255A3 HUP0104255A3 (en) | 2002-12-28 |
Family
ID=26805489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104255A HUP0104255A3 (en) | 1998-11-12 | 1999-11-12 | An pharmaceutical composition suitable for inhalation |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1128813B1 (hu) |
JP (1) | JP2002529393A (hu) |
KR (1) | KR20010111564A (hu) |
CN (1) | CN100358494C (hu) |
AT (1) | ATE353630T1 (hu) |
AU (1) | AU766703B2 (hu) |
CA (1) | CA2351063A1 (hu) |
CZ (1) | CZ20011581A3 (hu) |
DE (1) | DE69935154T2 (hu) |
ES (1) | ES2281199T3 (hu) |
HU (1) | HUP0104255A3 (hu) |
IL (1) | IL143046A0 (hu) |
MX (1) | MXPA01004828A (hu) |
NZ (1) | NZ511568A (hu) |
PL (1) | PL347630A1 (hu) |
WO (1) | WO2000027359A1 (hu) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030185761A1 (en) | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20040136914A1 (en) | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
WO1999016417A1 (en) | 1997-10-01 | 1999-04-08 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
AU5958200A (en) * | 1999-07-08 | 2001-01-30 | Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Pulmonary delivery of liposome-encapsulated cannabinoids |
US7648696B2 (en) | 1999-08-20 | 2010-01-19 | Unimed Pharmaceuticals, Llc | Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
US6747058B1 (en) | 1999-08-20 | 2004-06-08 | Unimed Pharmaceuticals, Inc. | Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor |
US6645467B2 (en) * | 1999-11-28 | 2003-11-11 | Scientific Development And Research, Inc. | Composition and method for decreasing upper respiratory airway resistance |
GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
CA2432319A1 (en) | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
WO2002089816A1 (en) * | 2001-05-02 | 2002-11-14 | Novartis Ag | Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
WO2002094233A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antiemetics through an inhalation route |
US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
JP2005527639A (ja) | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Rna干渉の治療的利用のための方法及び組成物 |
US9186322B2 (en) | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
DK2363114T3 (da) | 2002-10-29 | 2015-06-22 | Insmed Inc | Opretholdt afgivelse af anti-infektionsmidler |
US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
AU2004238076A1 (en) * | 2003-05-09 | 2004-11-25 | Novosom Ag | Injectable liposomal depots for delivering active ingredients |
US20040234699A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
US20040265238A1 (en) | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
JP4649841B2 (ja) * | 2004-02-18 | 2011-03-16 | コニカミノルタエムジー株式会社 | リポソーム含有製剤の製造方法、およびリポソーム含有製剤 |
AU2006230436B2 (en) | 2005-03-31 | 2011-11-24 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
WO2007053696A2 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
PT1962805T (pt) * | 2005-12-08 | 2016-10-05 | Insmed Inc | Composições de anti-infeciosos baseadas em lípidos para tratamento de infeções pulmonares |
US7846908B2 (en) | 2006-03-16 | 2010-12-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of TGF-beta and therapeutic uses thereof |
BRPI0712034A2 (pt) | 2006-05-19 | 2012-01-10 | Alnylam Pharmaceuticals Inc | modulação de rnai de aha e usos terapêuticos do mesmo |
US8268347B1 (en) * | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
CN102037123A (zh) | 2008-04-04 | 2011-04-27 | 卡兰多制药股份有限公司 | Epas1抑制剂的组合物和用途 |
WO2009143011A1 (en) * | 2008-05-20 | 2009-11-26 | Novartis Ag | Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
PL2413902T3 (pl) * | 2009-03-18 | 2020-01-31 | Incarda Therapeutics, Inc. | Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne |
MX2013001325A (es) * | 2010-08-05 | 2013-10-28 | Piramal Entpr Ltd | Formulacion de microparticulas para la administracion pulmonar de farmacos de moleculas anti-infecciosas para el tratamiento de enfermedades infecciosas. |
JP6402097B2 (ja) | 2012-05-21 | 2018-10-10 | インスメッド インコーポレイテッド | 肺感染症を処置するためのシステム |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
MX2015006681A (es) | 2012-11-29 | 2016-04-06 | Insmed Inc | Formulaciones de vancomicina estabilizadas. |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
CN105142631A (zh) | 2013-01-14 | 2015-12-09 | 健康诊所有限公司 | 抗癌药物和用途 |
EP2991634A1 (en) | 2013-04-30 | 2016-03-09 | Otitopic Inc. | Dry powder formulations and methods of use |
EP4119131A1 (en) | 2014-02-20 | 2023-01-18 | Otitopic Inc. | Dry powder formulations for inhalation |
WO2015175939A1 (en) | 2014-05-15 | 2015-11-19 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
CN114847965A (zh) | 2016-02-01 | 2022-08-05 | 英凯达治疗公司 | 电子监测联合吸入药理学疗法管理心律失常 |
JP6478959B2 (ja) * | 2016-09-07 | 2019-03-06 | 株式会社富士薬品 | 粒子含有組成物を製造するためのシステム及び方法 |
AU2018266199A1 (en) | 2017-05-10 | 2019-11-07 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
EP3684338A4 (en) | 2017-09-22 | 2021-06-23 | Otitopic Inc. | DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE |
WO2019175290A1 (en) * | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
EP3768378A4 (en) | 2018-03-22 | 2021-11-17 | InCarda Therapeutics, Inc. | INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE |
EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS |
EP4272731A3 (en) | 2018-12-11 | 2024-02-14 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
WO2021071967A1 (en) * | 2019-10-09 | 2021-04-15 | Island Breeze Systems Ca, Llc | Compositions for pulmonary delivery of cannabinoids and associated methods and systems |
CA3210753A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
WO2023198757A1 (en) | 2022-04-14 | 2023-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8322178D0 (en) * | 1983-08-17 | 1983-09-21 | Sterwin Ag | Preparing aerosol compositions |
US5340587A (en) * | 1985-05-22 | 1994-08-23 | Liposome Technology, Inc. | Liposome/bronchodilator method & System |
EP0223831B1 (en) * | 1985-05-22 | 1992-07-15 | Liposome Technology, Inc. | Liposome inhalation method and system |
US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
JPH05507090A (ja) * | 1990-05-08 | 1993-10-14 | リポサーム テクノロジー インコーポレイテッド | 直接噴霧乾燥された薬剤/脂質粉末組成物 |
US5094388A (en) * | 1991-01-23 | 1992-03-10 | Chapman Jr Luther | Portable drinking fountain for children |
EP0625207A1 (en) * | 1991-12-17 | 1994-11-23 | The Regents Of The University Of California | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
-
1999
- 1999-11-12 DE DE69935154T patent/DE69935154T2/de not_active Expired - Fee Related
- 1999-11-12 NZ NZ511568A patent/NZ511568A/en unknown
- 1999-11-12 WO PCT/US1999/026858 patent/WO2000027359A1/en not_active Application Discontinuation
- 1999-11-12 KR KR1020017006029A patent/KR20010111564A/ko not_active Application Discontinuation
- 1999-11-12 HU HU0104255A patent/HUP0104255A3/hu unknown
- 1999-11-12 AT AT99958945T patent/ATE353630T1/de not_active IP Right Cessation
- 1999-11-12 CA CA002351063A patent/CA2351063A1/en not_active Abandoned
- 1999-11-12 EP EP99958945A patent/EP1128813B1/en not_active Expired - Lifetime
- 1999-11-12 PL PL99347630A patent/PL347630A1/xx not_active Application Discontinuation
- 1999-11-12 CN CNB998152811A patent/CN100358494C/zh not_active Expired - Fee Related
- 1999-11-12 CZ CZ20011581A patent/CZ20011581A3/cs unknown
- 1999-11-12 JP JP2000580590A patent/JP2002529393A/ja active Pending
- 1999-11-12 MX MXPA01004828A patent/MXPA01004828A/es unknown
- 1999-11-12 IL IL14304699A patent/IL143046A0/xx unknown
- 1999-11-12 ES ES99958945T patent/ES2281199T3/es not_active Expired - Lifetime
- 1999-11-12 AU AU16212/00A patent/AU766703B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
IL143046A0 (en) | 2002-04-21 |
JP2002529393A (ja) | 2002-09-10 |
MXPA01004828A (es) | 2002-09-18 |
PL347630A1 (en) | 2002-04-22 |
EP1128813A4 (en) | 2004-08-18 |
EP1128813A1 (en) | 2001-09-05 |
CN1332626A (zh) | 2002-01-23 |
WO2000027359A1 (en) | 2000-05-18 |
ES2281199T3 (es) | 2007-09-16 |
EP1128813B1 (en) | 2007-02-14 |
CA2351063A1 (en) | 2000-05-18 |
CZ20011581A3 (cs) | 2001-12-12 |
HUP0104255A3 (en) | 2002-12-28 |
CN100358494C (zh) | 2008-01-02 |
DE69935154T2 (de) | 2007-10-25 |
AU766703B2 (en) | 2003-10-23 |
AU1621200A (en) | 2000-05-29 |
KR20010111564A (ko) | 2001-12-19 |
ATE353630T1 (de) | 2007-03-15 |
NZ511568A (en) | 2003-08-29 |
DE69935154D1 (de) | 2007-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104255A2 (hu) | Inhalációra alkalmas gyógyászati készítmény | |
TR199802108T2 (xx) | �bandronat i�eren oral farmas�tik bir form�lasyon. | |
CA2329005A1 (en) | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems | |
BR9807076B1 (pt) | "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" | |
ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
ES2089011T3 (es) | Excipiente lipidico de administracion nasal y aplicacion topica. | |
ATE387430T1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
DE69318503D1 (de) | Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung | |
DE69531741D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe | |
ATE554750T1 (de) | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen | |
HUP0302319A2 (hu) | Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására | |
CA2335065A1 (en) | Pharmaceutical formulations for aerosols with two or more active substances | |
KR970704422A (ko) | 투여용 약제학적 조성물 | |
RU94045950A (ru) | Фармацевтический препарат и способ его приготовления | |
DE69931930D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
SE9301171D0 (sv) | Pharmaceutical composition containing lipophilic drugs | |
EP0693924A4 (en) | METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS | |
HUP0303719A2 (hu) | Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra | |
DE60126433D1 (de) | Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen | |
IL162496A0 (en) | Pharmaceutical compositions containing cyclosporin | |
BRPI9916820B8 (pt) | composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método | |
ATE226065T1 (de) | Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung | |
CA2251656A1 (en) | Pharmaceutical compositions containing tyloxapol for administration to the respiratory tract | |
AU2503900A (en) | Sulfated phosphatidylinositols, their preparation and use |